B M Massie
- Aspirin use in chronic heart failure: what should we recommend to the practitioner?Barry M Massie
Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco, California, USA
J Am Coll Cardiol 46:963-6. 2005..These results suggest that aspirin should not be routinely used in CHF patients and be avoided in those with refractory CHF, but that it may be beneficial in patients with recent infarction or multiple vascular risk factors...
- Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and SurvivalB M Massie
Department of Medicine, University of California San Francisco and the Department of Veterans Affairs Medical Center, USA
Arch Intern Med 161:165-71. 2001..The present study examines the safety and tolerability of high- compared with low-dose lisinopril in CHF...
- Clinical trials in diastolic heart failureBarry M Massie
Cardiology Division, San Francisco VAMC, Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco, CA, USA
Prog Cardiovasc Dis 47:389-95. 2005..This article reviews the recent and ongoing trials in patients with diastolic heart failure, which hopefully will lead to improved treatment and outcomes...
- Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial InvestigatorsB M Massie
Department of Medicine, University of California, San Francisco, USA
J Card Fail 4:3-8. 1998..This study was designed to determine regional differences in patient characteristics and medication use among patients entered into an international heart failure trial...
- Irbesartan in patients with heart failure and preserved ejection fractionBarry M Massie
University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco 94121, USA
N Engl J Med 359:2456-67. 2008..Therefore, we studied the effects of irbesartan in patients with this syndrome...
- Rolofylline, an adenosine A1-receptor antagonist, in acute heart failureBarry M Massie
University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121, USA
N Engl J Med 363:1419-28. 2010....
- Predictors of clinical outcomes in patients given carvedilol for heart failureBarry Greenberg
University of California, San Diego, School of Medicine, San Diego, California, USA
Am J Cardiol 98:1480-4. 2006..In this unselected community population, these historical factors were better predictors of risk than the left ventricular ejection fraction...
- Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trialBarry M Massie
Department of Veterans Affairs, San Francisco, CA, USA
Circulation 119:1616-24. 2009..The objective of this study was to determine the optimal antithrombotic agent for heart failure patients with reduced ejection fractions who are in sinus rhythm...
- Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trialMichael R Zile
RHJ Department of Veterans Affairs Medical Center and Medical University of South Carolina, Division of Cardiology, Department of Medicine, Charleston, SC 29425, USA
Circulation 121:1393-405. 2010....
- The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristicsBarry M Massie
Cardiology Division, San Francisco Veterans Affairs Medical Center, CA 94121, USA
J Card Fail 10:101-12. 2004..The WATCH trial will help define the optimal approach to antithrombotic therapy in the contemporary management of patients with chronic heart failure resulting from left ventricular systolic dysfunction...
- Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practiceBarry M Massie
Veterans Affairs Medical Center and University of California San Francisco, San Francisco, CA, USA
Am J Cardiol 99:1263-8. 2007..In conclusion, without a control group, the effect of carvedilol on outcomes is not conclusive and trials of carvedilol in patients with HF and preserved EF should be undertaken...
- Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation studyBarry Greenberg
University of California, Advanced Heart Failure Treatment Program, San Diego, California 92103 8411, USA
J Am Coll Cardiol 50:600-6. 2007..This study sought to assess the pharmacokinetics and clinical effects of oral BG9928 in heart failure (HF) patients...
- Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trialsP A Heidenreich
Department of Health Research and Policy, Stanford University, California, USA
J Am Coll Cardiol 30:27-34. 1997..We sought to evaluate the current evidence for an effect of beta-blockade treatment on mortality in patients with congestive heart failure (CHF)...
- Cardiology participation improves outcomes in patients with new-onset heart failure in the outpatient settingMaria Ansari
Cardiology Division, San Francisco VAMC, San Francisco, California 94121, USA
J Am Coll Cardiol 41:62-8. 2003..This study examined the outcomes of new-onset heart failure (HF) outpatients managed by cardiologists and primary care (PC) physicians...
- Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic functionMaria Ansari
Cardiology Division, San Francisco VAMC, CA 94121, USA
Am Heart J 146:115-20. 2003..The clinical presentation and outcomes of patients with heart failure and preserved systolic function have not been well characterized in the outpatient setting...
- Silent cerebral infarction in heart failure: vascular or thromboembolic?Ronald S Freudenberger
Department of Medicine, Heart Failure and Transplant Cardiology Program, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
J Card Fail 11:490-1. 2005..Are we underestimating the occurrence of silent cerebral infarction, or can this finding be accounted for by concomitant conditions?..
- Beta-blocker dosing in community-based treatment of heart failureMichael B Fowler
Division of Cardiovascular Medicine, Stanford University Medical Center, Palo Alto, CA, USA
Am Heart J 153:1029-36. 2007..Community patients with heart failure (HF) are older, less often treated by HF specialists, and have more comorbidity than those in randomized clinical trials. These differences might affect beta-blocker prescribing in HF...
- The year in heart failure: 2004Barry M Massie
Cardiology Division, San Francisco VAMC, San Francisco, CA 94121, USA
J Card Fail 11:1-6. 2005
- Improving guideline adherence: a randomized trial evaluating strategies to increase beta-blocker use in heart failureMaria Ansari
Cardiology Division, San Francisco VA Medical Center, 4150 Clement St, San Francisco, Calif 94121, USA
Circulation 107:2799-804. 2003..This study evaluated interventions for implementing a new practice guideline advocating the use of beta-blockers for heart failure patients...
- Congestive heart failure with preserved systolic function in a statewide sample of community hospitalsK W Dauterman
Department of Medicine, University of California, San Francisco, CA 94121, USA
J Card Fail 7:221-8. 2001..21; 95% CI, 0.92-1.58). CONCLUSIONS: CHF with PrSF seems to be associated with high mortality and morbidity rates, but ACE inhibitors may not produce comparable benefit in this group as in patients with ReSF...
- Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectorisB M Massie
University of California, San Francisco, USA
Am J Hypertens 11:95S-102S. 1998..Mibefradil was safe and well tolerated in all studies...
- Angiotensin-converting enzyme inhibition in mild to moderate congestive heart failure: an evolving approachB M Massie
University of California, San Francisco
Am J Hypertens 1:402S-409S. 1988..A growing body of investigational data and clinical experience indicates that the ACEIs achieve these goals. As a result, they are being used with increasing frequency in patients with milder grades of heart failure...
- Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular functionC D Frances
Veterans Affairs Medical Center 111A1, 4150 Clement St, San Francisco, CA 94121, USA
Arch Intern Med 160:2645-50. 2000....
- Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trialMichael G Shlipak
General Internal Medicine Section, San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121, USA
J Am Soc Nephrol 15:2195-203. 2004..Renal dysfunction is strongly associated with mortality in stable outpatients with heart failure, notably in patients with estimated GFR <50 ml/min per 1.73 m(2). The effect of digoxin did not differ by level of renal function...
- What is the meaning of LIFE? Implications of the Losartan Intervention for Endpoint reduction in hypertension trial for heart failure physiciansBarry M Massie
Cardiology Section, Veterans Affairs Medical Center, San Francisco, California 94121, USA
J Card Fail 8:197-201. 2002
- Aligning quality and payment for heart failure care: defining the challengesEdward P Havranek
Division of Cardiology, Department of Medicine, Denver Health Medical Center and University of Colorado HSC, Denver, Colorado 80204 4507, USA
J Card Fail 9:251-4. 2003..This article describes each of these challenges in turn...
- 2003: The year in heart failureBarry M Massie
Cardiology 111C, Veterans Affairs Medical Center San Francisco, VA Hospital, 4150 Clement Street, San Francisco, CA 94121, USA
J Card Fail 10:1-3. 2004
- New York Heart Association functional class predicts exercise parameters in the current eraStuart D Russell
Department of Medicine, Johns Hopkins Hospital, Baltimore, MD 21287, USA
Am Heart J 158:S24-30. 2009..Using baseline data from the HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing) study, we examined this relationship...
- Failure of benefit and early hazard of bucindolol for Class IV heart failureJeffrey L Anderson
Division of Cardiology, LDS Hospital, University of Utah, Salt Lake City 84143, USA
J Card Fail 9:266-77. 2003..The risks and benefits of beta-blockade with bucindolol were assessed in heart failure (HF) patients with Class IV symptoms within the Beta-blocker Evaluation of Survival Trial (BEST)...
- Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registryJoseph A Franciosa
Mount Sinai School of Medicine and Weill Medical College, Cornell University, New York, NY, USA
Am Heart J 148:718-26. 2004..beta-Blockers reduce morbidity and mortality rates in heart failure (HF) clinical trials, but it is unknown whether these findings persist in the community setting...
- Neurohormonal blockade in chronic heart failure. How much is enough? Can there be too much?Barry M Massie
J Am Coll Cardiol 39:79-82. 2002
- Risk stratification after hospitalization for decompensated heart failureG Michael Felker
Duke Clinical Research Institute, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
J Card Fail 10:460-6. 2004..We used data from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study to develop a model that would predict outcomes in patients with decompensated HF...
- The prognostic importance of different definitions of worsening renal function in congestive heart failureStephen S Gottlieb
Division of Cardiology, University of Maryland School of Medicine and the D V A Medical Center, Baltimore, Maryland 21201, USA
J Card Fail 8:136-41. 2002..We therefore compared the prognostic importance of various definitions of worsening renal function in 1,002 patients hospitalized for congestive heart failure (CHF)...
- The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and designClyde W Yancy
Baylor University Medical Center, Heart and Vascular Institute, Dallas, TX 75246, USA
Am Heart J 153:478-84. 2007..Within a prespecified subset of high-risk patients, a potential signal of benefit on a combined end point of mortality and cardiovascular hospitalization was identified...
- Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registryWilliam T Abraham
Division of Cardiovascular Medicine, The Ohio State University School of Medicine, Columbus, OH, USA
Congest Heart Fail 13:16-21. 2007..9% vs 7.5%, hazard ratio 1.2 vs 1.0, P=.276). Thus carvedilol was similarly effective in blacks and whites with HF in the community setting, consistent with carvedilol clinical trials...
- The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosisPaula T Einhorn
National Heart, Lung, and Blood Institute, Division of Epidemiology and Clinical Applications, Bethesda, MD 20892 7936, USA
Am Heart J 153:42-53. 2007..However, questions have been raised regarding the validity of the HF diagnosis...
- Heart failure in community practice: relationship to age and sex in a beta-blocker registryJoseph A Franciosa
Zena and Michael A Wiener Cardiovascular Institute, Mt Sinai School of Medicine, and the Weill Medical College of Cornell University, New York, NY, USA
Congest Heart Fail 12:317-23. 2006..001). Characteristics of women and the elderly with HF in the community suggest increased risk, but both populations respond well after initiating carvedilol...
- Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trialMichael S Cuffe
Northwestern University Medical School, Division of Cardiology, 201 E Huron St, Galter 10 240, Chicago, IL 60611, USA
JAMA 287:1541-7. 2002..Although intravenous inotropic therapy usually produces beneficial hemodynamic effects and is labeled for use in the care of such patients, the effect of such therapy on intermediate-term clinical outcomes is uncertain...
- Chronic heart failure: a report from the Dartmouth Diastole DiscoursesMiguel A Quinones
Department of Cardiology, The Methodist Hospita, Methodist DeBakey Heart Center, Houston, TX 77030, USA
Congest Heart Fail 12:162-5. 2006..Despite a wide diversity of expressed opinions, several areas of discussion ultimately led to the consensus expressed in this document...
- The clinical challenge of cardiorenal syndromeMichael G Shlipak
Circulation 110:1514-7. 2004
- Relationship between heart failure treatment and development of worsening renal function among hospitalized patientsJaved Butler
Vanderbilt University, Nashville, Tenn, USA
Am Heart J 147:331-8. 2004..Whether treatment for HF contributes to WRF is unknown. In this study, we sought to assess whether acute treatment for patients who were hospitalized with HF contributes to WRF...
- Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failureDaniel E Forman
Section of Cardiology, Boston Medical Center, Boston, Massachusetts 02188, USA
J Am Coll Cardiol 43:61-7. 2004..The goal of this study was to determine the prevalence of worsening renal function (WRF) among hospitalized heart failure (HF) patients, clinical predictors of WRF, and hospital outcomes associated with WRF...
- Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot studyMilton Packer
College of Physicians and Surgeons, Columbia University, New York, New York, USA
J Card Fail 11:12-20. 2005..Endothelin receptor antagonism produces favorable short-term hemodynamic effects in heart failure, but the clinical effects of longer term therapy have not been evaluated...
- A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUSMichael J Domanski
Clinical Trials Group, National Heart, Lung, and Blood Institute NIH, 6701 Rockledge Drive, Room 8146, Bethesda, MD 20892 7936, USA
J Card Fail 9:354-63. 2003..These findings are further compared with COPERNICUS, which entered patients with more severe heart failure...
- The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and designPeter Carson
Department of Veterans Affairs Medical Center, Georgetown University Hospital, Washington, DC 20420, USA
J Card Fail 11:576-85. 2005..Although 40% to 50% of patients with chronic heart failure (HF) have relatively preserved systolic function (PSF), few trials have been conducted in this population and treatment guidelines do not include evidence-based recommendations...
- The year in heart failure 2005Barry M Massie
J Card Fail 12:1-9. 2006
- Evidence-based use of levosimendan in different clinical settingsLeonardo De Luca
Division of Cardiology, European Hospital, Rome, Italy
Eur Heart J 27:1908-20. 2006..This review summarizes the evidence from published scientific literature regarding the use of levosimendan in various clinical settings...
- Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failureMilton Packer
University of Texas Southwestern Medical Center, Dallas, Texas 75390 8822, USA
J Am Coll Cardiol 47:2245-52. 2006..This study sought to assess the potential utility of impedance cardiography (ICG) in predicting clinical deterioration in ambulatory patients with heart failure (HF)...
- Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) StudyAlan S Go
Division of Research, Kaiser Permanente of Northern California, 2000 Broadway St, 3rd Floor, Oakland, California 94612 2304, USA
Circulation 113:2713-23. 2006..It is unclear, however, whether this relation is explained by underlying kidney disease, treatment differences, or associated comorbidity...
- A comment on COMET: how to interpret a positive trial?Barry M Massie
J Card Fail 9:425-8. 2003